MDG1 Stock Overview
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.96 |
| 52 Week High | €2.85 |
| 52 Week Low | €1.40 |
| Beta | 0.85 |
| 1 Month Change | -17.16% |
| 3 Month Change | 38.65% |
| 1 Year Change | 11.71% |
| 3 Year Change | -50.69% |
| 5 Year Change | -78.08% |
| Change since IPO | -99.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDG1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.3% | -5.1% | -2.0% |
| 1Y | 11.7% | -21.1% | -0.3% |
Return vs Industry: MDG1 exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: MDG1 exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| MDG1 volatility | |
|---|---|
| MDG1 Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MDG1's share price has been volatile over the past 3 months.
Volatility Over Time: MDG1's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 76 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| MDG1 fundamental statistics | |
|---|---|
| Market cap | €47.16m |
| Earnings (TTM) | -€16.18m |
| Revenue (TTM) | €6.03m |
7.8x
P/S Ratio-2.9x
P/E RatioIs MDG1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDG1 income statement (TTM) | |
|---|---|
| Revenue | €6.03m |
| Cost of Revenue | €1.64m |
| Gross Profit | €4.39m |
| Other Expenses | €20.57m |
| Earnings | -€16.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 72.77% |
| Net Profit Margin | -268.10% |
| Debt/Equity Ratio | 0% |
How did MDG1 perform over the long term?
See historical performance and comparison